Inventor
SHEIKH AHMAD Y
US24 patents
⚠️ This page may combine multiple inventors who share the name “SHEIKH AHMAD Y”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABBVIE INC
17 patentsUS10017517B2Jul 10, 2018
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluorethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC41 citations98
US11198697B1Dec 14, 2021
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC29 citations97
US11186584B2Nov 30, 2021
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC28 citations97
US10981923B2Apr 20, 2021
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC32 citations97
US9879018B2Jan 30, 2018
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl and solid state forms thereof
ABBVIE INC42 citations95
US9879019B2Jan 30, 2018
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC42 citations94
US11680069B2Jun 20, 2023
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC6 citations93
US11661425B2May 30, 2023
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC9 citations93
US11512092B2Nov 29, 2022
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC21 citations93
US9856286B2Jan 2, 2018
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
ABBVIE INC14 citations90
US12110298B2Oct 8, 2024
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ABBVIE INC1 citations83
US11117927B2Sep 14, 2021
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
ABBVIE INC3 citations71
US9469673B2Oct 18, 2016
Crystaline forms of HCV inhibitor
ABBVIE INC4 citations68
US9321807B2Apr 26, 2016
Crystal forms
ABBVIE INC2 citations61
US9561181B2Feb 7, 2017
Crystal forms
ABBVIE INC0 citations51
US8592589B2Nov 26, 2013
Methods of treating cancer with a thieno[3,2-C]pyridine
ABBVIE INC0 citations51
US8357804B2Jan 22, 2013
Crystal forms of kinase inhibitors
ABBVIE INC0 citations51
ABBOTT LAB
2 patentsREATA PHARMACEUTICALS HOLDINGS LLC
2 patentsUS11873320B2Jan 16, 2024
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
REATA PHARMACEUTICALS HOLDINGS LLC2 citations70
US12384815B2Aug 12, 2025
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
REATA PHARMACEUTICALS HOLDINGS LLC0 citations59